We then asked whether ex vivo addition of a BRAF V600E-specific inhibitor to a tumor lysate could be used to distinguish between BRAF V600E and non-BRAF V600E thyroid tumors, as well as between recurrent and non-recurrent tumors. This evidence concerns the gene BRAF and thyroid tumor.